All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

Biogen's nusinersen high dose regimen receives CHMP positive opinion for 5q spinal muscular atrophy treatment
Antisense oligonucleotide, neurological, spinal muscular atrophy, SMN2 splicing modulator, high dose regimen - Read more

THE GOOD
Business Development & Partnerships

Merus, Halozyme collaborate on subcutaneous petosemtamab formulation with upfront payment and royalties
Licensing deal, oncology, antibody, drug delivery, milestone payments - Read more

PRESENTED BY PROMOVEO HEALTH
Contract Sales Reps = Fast Deployment + Lower Cost

We've built 100+ pharma sales teams for companies of all sizes, and we can help you.

We build agile field teams that scale based on your needs - all with fast deployment + lower cost than full-time reps.

See how flexible can work - click here to learn more.

✅ More Good News ✅

THE GOOD
Clinical Trials

Nuvalent reports Ph1/2 data for neladalkib targeting ALK-positive non-small cell lung cancer, prepares FDA filing
Small molecule, cancer, tyrosine kinase inhibitor, non-small cell lung cancer, ALK-positive - Read more

LEO Pharma's tralokinumab meets Ph3b ADHAND trial endpoints for moderate-to-severe hand atopic dermatitis
Antibody, autoimmune, monoclonal antibody, atopic dermatitis, IL-13 inhibitor, dermatology - Read more

BeOne Medicines reports positive Ph3 results for ZIIHERA (zanidatamab) plus TEVIMBRA in HER2-positive gastroesophageal adenocarcinoma
Antibody, cancer, bispecific antibody, gastroesophageal adenocarcinoma, HER2 target, combination therapy - Read more

Jazz Pharmaceuticals' Ziihera (zanidatamab) hits Ph3 goals in HER2-positive gastroesophageal adenocarcinoma, FDA filing planned
Antibody, cancer, bispecific antibody, gastroesophageal adenocarcinoma, HER2 target, combination therapy - Read more

THE GOOD
Company Incubation

Bayer officially opens Beijing incubator, names Puhe BioPharma and Youngen Technology as initial occupants
Small molecule, oncology, strategic, operational - Read more

THE GOOD
Fundraises

Solve Therapeutics raises $120M, advancing ADC pipeline with novel linker technology
Oncology, antibody-drug conjugate, clinical-stage, solid tumors - Read more

Artios Pharma raises $115M Series D, advancing oncology pipeline including pancreatic/colorectal cancer treatments
Cancer, small molecule, clinical-stage, DNA damage response - Read more

Captain T Cell raises €20M ($23.2M) equity round, advancing TCR-T therapies for solid tumors
Cell therapy, oncology, TCR-T, clinical-stage - Read more

Inventiva raises $172.5M public offering, developing oral MASH therapies
Metabolic disease, oral therapy, clinical-stage, MASH - Read more

MitoRx raises $7.2M pre-Series A, mitochondrial-targeted obesity treatment preserving lean mass
Obesity, small molecule, mitochondrial-targeted, preclinical - Read more

Imbria Pharmaceuticals extends Series B financing, advancing ninerafaxstat for cardiovascular diseases
Cardiovascular, clinical-stage, small molecule, first-in-class - Read more

THE GOOD
Investments

Scottish Brain Sciences opens third Alzheimer's research centre in Aberdeen, expanding early diagnosis trial access
Neurological, precision medicine, strategic, operational - Read more

THE GOOD
Mergers & Acquisitions

Johnson & Johnson acquires Halda Therapeutics for $3B cash to boost cancer pipeline toward $50B sales target
Small molecule, oncology, strategic, major transaction - Read more

XenoTherapeutics acquires struggling Repare Therapeutics for $78.2M after layoffs and partnering setbacks
Small molecule, oncology, strategic, major transaction - Read more

Biogen completes acquisition of Alcyone Therapeutics, adding CNS drug delivery device technology
Medical device, neurological, strategic, major transaction - Read more

THE GOOD
Politics & Policy

Trump cuts Swiss pharmaceutical tariffs to 15% for Novartis, Roche in new trade deal
Pharmaceuticals, regulatory, strategic, major transaction - Read more

THE GOOD
Product Launches

Terray Therapeutics debuts EMMI AI platform that outperforms chemists in selecting molecules for synthesis
Small molecule, drug discovery, strategic, operational - Read more

Sandoz launches Tyruko, first US Tysabri biosimilar, after JCV antibody test delays resolved
Monoclonal antibody, neurological, strategic, competitive - Read more

THE GOOD
Regulatory

FDA streamlines biosimilar approvals to cut $100M development costs, but patent challenges remain obstacle
Biosimilars, regulatory, cost reduction, competitive, financial - Read more

PRESENTED BY YOU?
Get the attention of 2300+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Clinical Trials

Genmab discontinues GEN1160 antibody-drug conjugate Ph1/2 trial in renal cell carcinoma due to low enrollment
Antibody-drug conjugate, cancer, renal cell carcinoma, non-Hodgkin lymphoma, ovarian cancer, endometrial cancer - Read more

THE BAD
Earnings & Finances

TC BioPharm files for insolvency, halting TCB008 and gamma delta cell therapy development amid funding challenges
Cell therapy, oncology, financial, operational - Read more

THE BAD
Layoffs

Nxera cuts 15% of workforce, reduces R&D spending by $22.6M targeting profitability
GPCR modulators, metabolic disorders, operational, cost reduction - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here